Valeant Pharmaceuticals has reportedly upped its unsolicited offer to acquire the maker of Botox.
Reports say Valeant increased its bid to $49.4 billion to acquire Canada-based Allergan in hopes of swaying approval from the firm and its shareholders. The original acquisition offer was first introduced last month.
The deal is reportedly part …read more
Source: Global Competition Law Blogs